Official Title
Open-Label, Non-Randomized Study to Evaluate Anti-Malarial/Anti-Infective Combination Therapies in Patients With Confirmed COVID-19 Infection
Brief Summary

This study will evaluate anti-malarial/anti-infective single-agent and in combination for patients with confirmed COVID-19 infection. The first combination to be evaluated is atovaquone and azithromycin.

Detailed Description

This is an open-label, non-randomized study to evaluate anti-malarial/anti-infective single-agents and combination therapies for patients with confirmed COVID-19 infection requiring therapy as determined by risk factors for complication (age, comorbid illness) or the presence of respiratory compromise. The first combination to be evaluated is atovaquone/azithromycin. Other combinations may be added to the study at future amendments as information of potential benefit arises. The first part of the study will enroll 25 evaluable male and female patients 18 years of age or older with confirmed COVID-19 infection.

Recruiting
COVID19

Drug: Atovaquone/Azithromycin
Atovaquone 750 mg PO Q12H for up to 10 Days Azithromycin 500 mg PO Daily 1 followed by 250 mg PO Daily for up to 10 days (days 2-10)
Atovaquone/Azithromycin
Other Name: Mepron/Zithromax

Eligibility Criteria

Inclusion Criteria:

- Male and Female patients age 18 years or older

- COVID-19 confirmed positive test results

- High risk for complications including with Medium (5-6) or High (More than or equal to 7) NEWS score

- Hematology criteria: ANC >500 cells/mcl, HGB >9 g/dl, Platelet count >75,000/mcl

- Metabolic criteria: Serum creatinine 30 ml/min, AST/ALT

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years~Maximum: 95 Years
Countries
United States
Locations

HonorHealth
Scottsdale, Arizona, 85258

Recruiting

Investigator: Karen Lewandowski, RN
Contact: 480-583-0760
klewandowski@honorhealth.com


Investigator: Heather Lane
Contact: 480-323-1081
hlane@honorhealth.com

Contacts

Karen Lewandowski, RN
480-583-0760
klewandowski@honorhealth.com

Heather Lane
480-323-1081
hlane@honorhealth.com

Michael Gordon, MD
Principal Investigator
HonorHealth Research Institute

HonorHealth Research Institute
NCT Number
MeSH Terms
Infection
Azithromycin
Atovaquone